On the recordOctober 16, 2017
As part of such scrutiny, policymakers should examine whether brand drug manufacturers may abuse their market power to delay or impede generic entry.
Source
congress.govPat Roberts: “As part of such scrutiny, policymakers should examine whether brand drug manufacturers may abuse their market power to…”
Editor's note · Context
Roberts emphasizes the need to scrutinize brand drug manufacturers' market power.
Share
More from Pat Roberts
Mar 13, 2018
Show me a nation that cannot feed itself, and I'll show you a nation in chaos.
Feb 28, 2018
Unfortunately, the Trump Administration is taking the National Labor Relations Board in the wrong direction.
Apr 10, 2018
But short-term, for goodness' sake, do not, in this business of playing your cards of trying to get a better deal for the United States or a better trade situation, do not do so at the expense of American agriculture, which is going…
Mar 21, 2018
I strongly agree with USTR's assessment that we have significant problems related to intellectual property and other market access-related issues with China.
Other voices in this conversation
